Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is an open label phase to trial for patients with recurrent or Stage IVB Cervical cancer. Patients will either receive Tisotumab Vedotin in combination with either pembrolizumab, carboplatin, or bevacizumab, or Tisotumab Vedotin as a monotherapy. All treatment will be administered via IV infusion. The primary endpoint of this study is to determine the incidences of dose limiting toxicities and adverse events. . (Genmab A/S IRB 2019-0838)

NRG GY018
2020-0075
A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCERCHEMORADIATION PLUS ATEZOLIZUMAB
VBL Therapeutics VB-111-701
2019-0189
The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!
New phone-based application available to all UC Cancer Center members and colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? Now, the UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all to use when recruiting patients into studies.

Application users are provided information on each of the Center’s recruiting studies to aid in screening and discussing study participation with patients. This includes study summaries, inclusion and exclusion criteria, other pertinent study information, and a streamlined way to contact the primary research coordinator for each study. IN ORDER TO START USING THIS APPLICATION, go to the website https://ctra.codehatcher.com on your phone and then add the application to your home screen. Your UC Cancer Center research team can also assist you. For further questions please reach out to Dr. Dylan Steen @ 908-208-6927, steendl@ucmail.uc.edu or Ginger Conway @859-992-5339, gingerconway8@gmail.com.
UC Cancer Center leads COVID-19 studies 

The UC Cancer Center has joined the fight against COVID-19 by researching the effects of the virus in cancer patients.
Click Here to Visit the UC Newsroom
All upcoming in person professional education events and Grand Rounds Events have  been temporarily suspended due to the COVID-19 outbreak until further notice. 
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA